We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.51 | -1.68% | 29.82 | 29.82 | 30.03 | 30.15 | 29.81 | 29.92 | 3,381,439 | 21:00:05 |
From May 2019 to May 2024
By Matt Grossman
Roche Holding AG has gained approval from the U.S. Food and Drug Administration for a diagnostic test used to determine whether patients with endometrial cancer will benefit from a particular treatment.
The test, called Ventana MMR RxDx, can help physicians decide whether an endometrial cancer patient should be treated with Jemperli, an anti-PD1 immunotherapy from GlaxoSmithKline PLC.
The test uses a comprehensive panel of DNA mismatch repair biomarkers tested by immunohistochemistry, Roche said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
April 23, 2021 06:32 ET (10:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
